골관절염 치료제 시장 : 시장 예측(2026-2032년)

The Osteoarthritis Therapeutics Market is projected to grow by USD 9.35 billion at a CAGR of 7.72% by 2032.

Osteoarthritis Therapeutics Executive Summary

Osteoarthritis therapeutics are moving beyond symptomatic pain relief toward integrated disease management that combines pharmacologic treatment, injectables, digital monitoring, rehabilitation, weight management, and procedure-sparing care pathways. Osteoarthritis is the most common form of arthritis globally and a leading contributor to disability, particularly among aging populations and people with obesity, prior joint injury, repetitive occupational loading, or reduced muscle strength. Current treatment approaches include oral and topical nonsteroidal anti-inflammatory drugs, acetaminophen in selected patients, intra-articular corticosteroids, hyaluronic acid in selected settings, physical therapy, assistive devices, bracing, and lifestyle interventions, with surgical referral reserved for advanced joint damage and severe functional limitation.

The therapeutic landscape is shaped by a persistent unmet need: patients require durable pain control, improved mobility, fewer systemic adverse events, and interventions that may slow structural progression rather than only mask symptoms. Regulatory agencies and clinical societies continue to emphasize evidence-based prescribing, patient phenotyping, opioid-sparing strategies, weight management, structured exercise, and shared decision-making. As a result, industry participants are focusing on safer analgesics, locally delivered therapies, regenerative and biologic approaches, companion diagnostics, real-world evidence, and digital tools that support adherence and long-term outcomes in knee, hip, hand, and spine osteoarthritis.

Transformative Shifts Reshaping Osteoarthritis Therapeutics

The osteoarthritis therapeutics landscape is undergoing transformative shifts driven by demographic pressure, scientific advances, and changing expectations from payers, clinicians, and patients. The first major shift is the transition from generalized pain management to phenotype-guided treatment. Osteoarthritis is increasingly understood as a heterogeneous disease involving inflammatory, metabolic, mechanical, bone-driven, and pain-sensitization pathways. This is encouraging development of targeted interventions and more precise patient selection in clinical trials.

A second shift is the move toward opioid-sparing and steroid-sparing care. Public health concerns related to opioid dependence and long-term safety concerns around repeated corticosteroid exposure have strengthened demand for topical therapies, non-opioid analgesics, physical therapy integration, and minimally invasive intra-articular options. Clinical practice has also placed greater emphasis on nonpharmacologic interventions such as structured exercise, weight reduction, bracing, patient education, and self-management programs.

A third shift is the growing importance of real-world evidence and patient-reported outcomes. Regulators, health technology assessors, and payers increasingly expect evidence on pain reduction, physical function, quality of life, durability of response, rescue medication use, safety, and healthcare utilization. Digital endpoints, wearable activity data, imaging biomarkers, and longitudinal registries are becoming more relevant as stakeholders seek to understand treatment performance outside controlled trial environments.

Finally, innovation is expanding from single-agent therapy to multimodal musculoskeletal care. Digital therapeutics, remote physiotherapy, AI-assisted imaging, biomarker-driven trial enrollment, and integrated orthopedic-rheumatology pathways are changing how osteoarthritis is diagnosed, monitored, and treated across the patient journey.

Cumulative Impact of Artificial Intelligence on Osteoarthritis Care

Artificial intelligence is becoming a cumulative force across osteoarthritis therapeutics by improving diagnosis, clinical trial design, treatment personalization, and post-treatment monitoring. In diagnostics, AI-enabled imaging analysis can support the assessment of joint space narrowing, cartilage loss, osteophytes, bone marrow lesions, synovitis patterns, and alignment changes on X-ray, MRI, and other imaging modalities. These tools can help identify structural progression earlier and reduce variability in radiographic interpretation when validated against clinical standards.

In drug development, machine learning is being applied to patient stratification, biomarker discovery, trial eligibility screening, and prediction of response to investigational therapies. Because osteoarthritis progresses slowly and displays substantial clinical heterogeneity, AI can help identify subgroups with inflammatory activity, rapid structural progression, metabolic risk factors, or centralized pain features, enabling more efficient study designs and more clinically meaningful endpoints.

AI also supports real-world care delivery. Predictive models can identify patients at risk of worsening pain, reduced mobility, falls, work impairment, or future joint replacement referral. Digital platforms using wearable sensors and smartphone-based assessments can track gait, activity, sleep, medication adherence, and rehabilitation engagement. For clinicians, this can improve follow-up timing and therapeutic adjustment; for payers, it can support value-based care; and for patients, it can enable earlier intervention and better self-management.

However, AI adoption requires validated algorithms, representative datasets, explainability, privacy safeguards, and integration into clinical workflows. Bias in imaging datasets, inconsistent data standards, and uncertain reimbursement for AI-enabled musculoskeletal tools remain barriers. The strongest near-term value lies in AI systems that complement clinical judgment, improve operational efficiency, and generate evidence for measurable improvements in pain, function, and care continuity.

Key Regional Insights Across Osteoarthritis Therapeutics

In Asia-Pacific, osteoarthritis therapeutics demand is closely linked to population aging, urban lifestyle changes, rising obesity rates in several countries, and improved access to specialty care. Japan and South Korea have advanced orthopedic and rheumatology infrastructure, while China, India, Australia, and Southeast Asian markets are expanding access to diagnostics, branded generics, injectables, physiotherapy, and digital health-enabled chronic disease management. Variability in reimbursement and out-of-pocket spending continues to influence treatment selection, with affordability shaping the use of topical NSAIDs, oral analgesics, intra-articular therapies, and rehabilitation services.

North America remains a highly evidence-driven region for osteoarthritis treatment, supported by broad clinical guideline adoption, established payer scrutiny, extensive use of real-world evidence, and strong demand for opioid-sparing pain management. The United States and Canada emphasize multidisciplinary care, physical therapy, weight management, assistive technologies, and careful pharmacologic selection due to concerns about cardiovascular, gastrointestinal, renal, and dependency-related risks associated with some therapies.

Latin America is characterized by a high burden of musculoskeletal disability, expanding access to generic medicines, and uneven availability of specialist services across urban and rural settings. Brazil and Mexico play important roles in regional treatment adoption, with demand shaped by public healthcare capacity, private insurance coverage, workforce constraints, and the need for cost-effective pain management and mobility-preserving interventions.

Europe demonstrates strong alignment with evidence-based clinical practice, pharmacovigilance, and health technology assessment. Countries across the region prioritize conservative care, topical NSAIDs where appropriate, structured exercise, patient education, and cautious use of intra-articular interventions based on clinical guidance. Reimbursement frameworks and national health systems influence access to innovative therapies, digital musculoskeletal programs, advanced imaging, and rehabilitation services.

The Middle East is seeing rising osteoarthritis burden associated with demographic change, obesity, sedentary lifestyles, and increased diagnosis of chronic musculoskeletal conditions. Gulf countries are investing in specialty care infrastructure, rehabilitation services, and digital health, while access patterns vary across the wider region. In Africa, osteoarthritis care is affected by limited specialist availability, variable diagnostic access, and affordability constraints, but the need for low-cost analgesics, community-based rehabilitation, and scalable mobility interventions is significant as aging and noncommunicable disease burdens increase.

Key Group Insights Influencing Osteoarthritis Therapeutics

Across ASEAN, osteoarthritis therapeutics are shaped by rapid population aging in several member states, growing urban healthcare access, and strong reliance on cost-effective oral and topical pain therapies. Rehabilitation services and intra-articular treatment availability are expanding in major cities, while rural access gaps sustain demand for affordable first-line therapies and primary care-based disease management.

The GCC is positioned around high healthcare investment, rising obesity prevalence, and increasing attention to chronic musculoskeletal conditions that affect productivity and quality of life. Care models in the region are moving toward specialist-led orthopedic and rheumatology services, medical tourism integration in selected locations, preventive health programs, and digital health adoption, creating opportunities for therapies and platforms that support long-term mobility management.

The European Union is defined by regulatory rigor, pharmacovigilance, clinical guideline adherence, and health technology assessment. Treatment adoption depends heavily on demonstrated clinical benefit, safety, cost-effectiveness, and compatibility with national reimbursement systems. EU-wide emphasis on healthy aging, workplace participation, and reduced surgical burden supports interest in preventive care, structured exercise, rehabilitation, and evidence-backed non-opioid interventions.

BRICS countries represent diverse but high-need osteoarthritis environments, combining large patient populations, expanding middle-class healthcare demand, and growing domestic capabilities in generics, biosciences, diagnostics, and digital health. China and India are especially important due to scale and rising chronic disease management needs, while Brazil, Russia, and South Africa face varied access, reimbursement, and infrastructure challenges that shape uptake of advanced osteoarthritis therapeutics.

The G7 group reflects mature healthcare systems where osteoarthritis therapeutics are evaluated through robust clinical evidence, payer controls, safety monitoring, and patient-centered outcomes. Aging demographics, high joint replacement utilization, and pressure to reduce long-term disability support continued demand for therapies that delay functional decline. NATO countries, overlapping substantially with North America and Europe, show strong emphasis on workforce readiness, rehabilitation, and musculoskeletal health among aging civilian and veteran populations, making mobility preservation and non-opioid pain management key priorities.

Key Country Insights for Osteoarthritis Therapeutics

The United States is a central environment for osteoarthritis therapeutics due to its high diagnosed burden, extensive use of clinical guidelines, strong focus on opioid-sparing pain care, and payer emphasis on outcomes and utilization management. Canada similarly prioritizes evidence-based prescribing, conservative management, rehabilitation, and equitable access, although provincial reimbursement variation can affect therapy availability. Mexico's osteoarthritis treatment environment is shaped by public-private healthcare segmentation, high demand for affordable analgesics, and improving access to specialist care in urban centers.

Brazil has a substantial musculoskeletal disease burden and growing demand for cost-effective therapies, rehabilitation, and injectable options, while broader access depends on public system capacity and private coverage. The United Kingdom emphasizes guideline-led management, exercise, weight management, topical NSAIDs, and careful selection of pharmacologic therapy within a publicly funded care model. Germany combines strong specialist care, rehabilitation infrastructure, and rigorous assessment of therapeutic value, supporting adoption where safety and functional benefit are clearly demonstrated. France maintains a structured healthcare environment with attention to reimbursement evidence and appropriate use of symptomatic therapies. Russia faces a large need for osteoarthritis management across a geographically broad population, with access varying by region and healthcare setting. Italy and Spain have aging populations and established rheumatology and orthopedic services, with ongoing pressure to manage chronic pain, preserve function, and limit unnecessary surgical escalation.

China is experiencing rising osteoarthritis diagnosis linked to aging, urbanization, obesity trends, and improved access to imaging and specialty care, creating demand for scalable pharmacologic, injectable, rehabilitation, and digital care options. India faces a large and growing osteoarthritis burden, particularly knee osteoarthritis, with treatment strongly influenced by affordability, generic medicine access, urban specialist availability, and increasing awareness of lifestyle-based management. Japan's super-aged population creates sustained need for mobility-preserving therapies, rehabilitation, fall-risk reduction, and safe long-term pain management. Australia emphasizes evidence-based musculoskeletal care, physiotherapy, weight reduction, and careful prescribing in line with national guidance. South Korea combines advanced healthcare infrastructure, strong diagnostic access, and growing digital health integration, supporting continued evolution toward personalized and monitored osteoarthritis management.

Actionable Recommendations for Osteoarthritis Therapeutics Leaders

Industry leaders should prioritize differentiated osteoarthritis therapeutics that address validated unmet needs: durable pain relief, functional improvement, reduced systemic adverse events, and evidence of benefit in clearly defined patient subgroups. Development strategies should incorporate phenotype-based trial enrollment, imaging and biochemical biomarkers, patient-reported outcomes, functional endpoints, and real-world evidence plans from the earliest stages.

Organizations should also invest in integrated care models that combine therapeutics with rehabilitation, digital adherence tools, remote monitoring, weight management, and lifestyle support. Partnerships with clinicians, payers, digital health providers, and rehabilitation networks can strengthen patient engagement and demonstrate practical value beyond symptom reduction. Given increasing scrutiny of opioids, repeated corticosteroid use, and broad systemic analgesic exposure, positioning around safety, opioid-sparing pathways, and function-first outcomes is essential.

For commercialization, stakeholders should tailor access strategies to regional healthcare realities. Mature healthcare systems require comparative evidence, pharmacoeconomic support, safety monitoring, and guideline alignment, while emerging markets require affordability, education, distribution reach, and scalable primary care integration. Organizations should prepare for stronger demand for transparency, post-market safety surveillance, and evidence that therapies reduce disability, improve daily activity, and support long-term musculoskeletal health.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available, verifiable sources, including clinical practice guidelines, regulatory publications, peer-reviewed medical literature, epidemiological studies, health authority documents, and musculoskeletal disease reports from recognized public health and professional bodies. The analysis focuses on treatment pathways, therapeutic innovation, regional access dynamics, disease burden indicators, regulatory considerations, safety signals, and technology adoption trends relevant to osteoarthritis therapeutics.

The methodology emphasizes triangulation of evidence across clinical, regulatory, and healthcare delivery sources to identify consistent patterns while avoiding unsupported claims. Insights are qualitatively assessed across regions, economic groups, and key countries based on healthcare infrastructure, reimbursement environment, demographic trends, clinical practice norms, and adoption of pharmacologic, injectable, rehabilitative, and digital musculoskeletal interventions. No market sizing, market share estimation, or forecasting is included.

Conclusion

Osteoarthritis therapeutics are entering a more personalized, evidence-driven, and digitally supported phase of development and delivery. The field is shifting from broad symptomatic treatment toward integrated care that prioritizes pain relief, physical function, safety, patient stratification, and long-term mobility. Aging populations, obesity, injury-related joint degeneration, and the need to reduce disability will continue to place osteoarthritis high on healthcare agendas worldwide.

The most successful strategies will be those that combine scientific differentiation with practical access, clinician trust, patient engagement, and measurable real-world outcomes. AI-enabled diagnostics, phenotype-guided treatment development, safer non-opioid therapies, and multimodal care platforms are expected to play an increasingly important role. For stakeholders across the osteoarthritis therapeutics ecosystem, the strategic priority is clear: deliver therapies and care models that improve mobility, reduce chronic pain burden, preserve function, and fit the economic and clinical realities of diverse healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Osteoarthritis Therapeutics Market, by Treatment Type

• 7.1. Introduction
• 7.2. Complementary Therapies
  • 7.2.1. Acupuncture
  • 7.2.2. Massage Therapy
  • 7.2.3. Nutritional Supplements
• 7.3. Drug Therapy
  • 7.3.1. Corticosteroid Injections
  • 7.3.2. Hyaluronic Acid Injections
  • 7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 7.3.4. Opioids
• 7.4. Physical Therapy
• 7.5. Surgery
  • 7.5.1. Arthroscopy
  • 7.5.2. Joint Replacement
  • 7.5.3. Osteotomy
    • 7.5.3.1. Femoral Osteotomy
    • 7.5.3.2. Tibial Osteotomy

8. Osteoarthritis Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral
• 8.4. Topical
• 8.5. Transdermal

9. Osteoarthritis Therapeutics Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Hospitals
• 9.4. Rehabilitation Centers

10. Osteoarthritis Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Osteoarthritis Therapeutics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Osteoarthritis Therapeutics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Osteoarthritis Therapeutics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AbbVie Inc.
• 15.2. Amgen Inc.
• 15.3. Anika Therapeutics, Inc.
• 15.4. AstraZeneca PLC
• 15.5. Bayer AG
• 15.6. Boehringer Ingelheim International GmbH
• 15.7. Cipla Ltd.
• 15.8. Doron Therapeutics
• 15.9. Eli Lilly and Company
• 15.10. Endo International plc
• 15.11. Ferring B.V.
• 15.12. Fidia Farmaceutici S.p.A
• 15.13. GSK PLC
• 15.14. Hanmi Pharm. Co., Ltd.
• 15.15. Hikma Pharmaceuticals PLC
• 15.16. Johnson & Johnson Services Inc.
• 15.17. Kitov Pharmaceuticals Ltd.
• 15.18. Mankind Pharma
• 15.19. Merck & Co.
• 15.20. Pacira BioSciences, Inc.
• 15.21. Par Health
• 15.22. Pfizer Inc.
• 15.23. Sanofi S.A.
• 15.24. Sun Pharmaceutical Industries Ltd.
• 15.25. Takeda Pharmaceutical Company
• 15.26. Teva Pharmaceutical Industries Ltd.
• 15.27. UCB S.A.
• 15.28. Viatris Inc.
• 15.29. Zydus Lifesciences Limited